Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

BioRestorative Therapies, Inc. (BRTX)

3.4399   0.08 (2.38%) 06-26 19:51
Open: 3.47 Pre. Close: 3.36
High: 3.47 Low: 3.32
Volume: 3,891 Market Cap: 13(M)
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.47 - 3.49 3.49 - 3.5
Low: 3.29 - 3.3 3.3 - 3.31
Close: 3.42 - 3.44 3.44 - 3.46

Technical analysis

as of: 2022-06-24 4:38:32 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 4.97     One year: 5.83
Support: Support1: 3.06    Support2: 2.55
Resistance: Resistance1: 4.26    Resistance2: 4.99
Pivot: 3.85
Moving Average: MA(5): 3.46     MA(20): 3.98
MA(100): 4.39     MA(250): 8.67
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 14.3     %D(3): 13.2
RSI: RSI(14): 39.4
52-week: High: 32  Low: 3.06
Average Vol(K): 3-Month: 25 (K)  10-Days: 16 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BRTX ] has closed above bottom band by 26.3%. Bollinger Bands are 3.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 22 Jun 2022
Highest paid executives on Long Island work at tiny biotech firm BioRestorative Therapies - Newsday

Wed, 22 Jun 2022
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company's ... - The Bakersfield Californian

Mon, 13 Jun 2022
BioRestorative Therapies Announces Clinical Site Initiation for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) - GlobeNewswire

Fri, 27 May 2022
BioRestorative Therapies : BRTX Presentation May 2022 - Marketscreener.com

Fri, 29 Apr 2022
BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease - GlobeNewswire

Tue, 12 Apr 2022
Tuesday 4/12 Insider Buying Report: BRTX, WMC - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 3 (M)
% Held by Insiders 2.92e+006 (%)
% Held by Institutions 19.5 (%)
Shares Short 77 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.622e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -57
Return on Assets (ttm) 191
Return on Equity (ttm) -122.7
Qtrly Rev. Growth 46000
Gross Profit (p.s.) -0.87
Sales Per Share -5.36
EBITDA (p.s.) 563.44
Qtrly Earnings Growth -40.9
Operating Cash Flow 0 (M)
Levered Free Cash Flow -3 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.65
Price to Cash Flow -50.24

Stock Dividends

Dividend 0
Forward Dividend 78550
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.